Fathom Therapeutics funding, valuation and investors

Fathom Therapeutics (formerly Atommap Corp.) is a New York-headquartered preclinical biotechnology company with a Boston office, founded by Huafeng Xu (CEO), Yujie Wu (CTO) and Jesús Izaguirre (Chief Computational Scientist). Its Microcosmos platform uses computational physics, quantum chemistry and machine learning to simulate molecular/protein motions and guide small-molecule design.

Its commercial model combines internal drug programs and external discovery partnerships, not a publicly priced self-serve SaaS tool.

FINANCING CHRONOLOGY AND NOVEMBER FALSE-FRESHNESS TRAP: The company-issued April 27, 2026 PR Newswire release announced an oversubscribed $47 million Series A, led by Sutter Hill Ventures, with Chemistry, Alexandria Venture Investments and NY Ventures.

On October 29 the company retrospectively said its Series A financing reached $55 million in MAY 2026, with Lilly Ventures also participating; the exact May closing date and the mechanics/timing of the $8M increase from the April disclosure were not specified. On November 6, Kos Biotechnology Partners disclosed its participation through Kos BioVentures in THAT SAME $55M round.

This DOES NOT establish another $55M in November, nor that Kos independently invested $55M. Kos's own cheque and Fathom's valuation are undisclosed. The $55M is the later total Series A figure; do not add $47M to it. No separate additional Series A close or seed round is fabricated.

SCIENTIFIC PRODUCT AND BUYER TOUR (illustrative; not hands-on verification): (1) A pharmaceutical discovery team specifies a disease-linked protein target and known molecular or assay data. (2) Fathom's scientists use Microcosmos to model conformational motion and transient cavities rather than relying on a single static crystal structure. (3) Candidate small molecules are designed or optimized against simulated target states.

(4) Wet-lab assays test potency, selectivity, cellular activity and liabilities, feeding results into iterative design. (5) Promising compounds enter animal efficacy and ADME/toxicology gates; IND-enabling work and clinical testing would be required before efficacy in humans can be claimed. Commercial collaboration economics, IP allocations, milestones and platform license fees are not publicly disclosed. This description is grounded in company statements, not a public product demo.

The original April release says the platform had generated candidates for a challenging target within six weeks and that a lead program was in animal efficacy studies. Fathom describes up to 10,000x faster protein-dynamics modeling versus unspecified baselines; this vendor figure is not a peer-reviewed head-to-head and says nothing by itself about clinical efficacy.

The company's 2026 BIO convention profile reports 12 discovery partnerships since founding and preclinical development, but these are issuer-provided figures, not audited paid-customer counts. The October 29 release introduced Bret Williams as Chief Scientific Officer to translate computational hits into therapeutic programs; this is a scientific development stage, not an approved drug or confirmed clinical benefit.

Comparisons with Schrödinger, Relay Therapeutics and QSimulate should distinguish simulation tools, development pipelines and partnerships.

Primary source 1 (original Apr $47M): https://www.prnewswire.com/news-releases/fathom-therapeutics-formerly-atommap-raises-47-million-in-oversubscribed-series-a-financing-to-translate-physics-and-ai-enabled-small-molecule-design-into-next-generation-medicines-302754272.html Primary source 2 (company's explicit May $55M): https://www.prnewswire.com/news-releases/fathom-therapeutics-appoints-bret-williams-as-chief-scientific-officer-to-translate-microcosmos-insights-into-a-therapeutic-portfolio-302923780.html Primary source 3 (Nov Kos participation, not new close): https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-investment-in-fathom-therapeutics-to-advance-novel-ai-driven-drug-discovery-platform-302931959.html 2026 BIO meeting issuer profile: https://convention.bio.org/2026-sessions-and-courses/fathom-therapeutics-inc